Tunable Functionality and toxicity studies of Titanium Dioxide Nanotube Layers

In this work, we have developed economic process to elaborate scalable titanium dioxide nanotube layers which show a tunable functionality. The titanium dioxide nanotube layers was prepared by electrochemical anodization of Ti foil in 0.4 wt% hydrofluoric acid solution. The nanotube layers structure and morphology were characterized using x-ray diffraction and scanning electron microscopy. The surface topography and wettability was studied according to the anodization time. The sample synthesized while the current density reached a local minimum displayed higher contact angle. Beyond this point, the contact angles decrease with the anodization time. Photo-degradation of acid orange 7 in aqueous solution was used as a probe to assess the photo-catalytic activity of titanium dioxide nanotube layers under UV irradiation. We obtained better photocatalitic activity for the sample elaborate at higher current density. Finally we use the Ciliated Protozoan T. pyriformis, an alternative cell model used for in vitro toxicity studies, to predict the toxicity of titanium dioxide nanotube layers in biological system. We did not observe any characteristic effect in the presence of the titanium dioxide nanotube layers on two physiological parameters related to this organism, non-specific esterases activity and population growth rate

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients"

Treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), has demonstrated significantly improved progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, when used in combination with endocrine therapies. However, limited data exists on its cutaneous adverse events (AE). The aim of our retrospective study was to investigate the prevalence, types and management of cutaneous AE during CDK4/6i. 79 adult advanced breast cancer patients affected by 125 skin adverse events during treatment with CDK4/6i were recruited at eleven centers. The most frequent cutaneous reactions were pruritus (49/79 patients), alopecia (25/79), and ec-zematous lesions (24/79). We showed that skin reactions are usually mild in severity, and prompt management may limit the negative impact on patients, facilitating beneficial continuation of oncologic treatment

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the treatment of metastatic colorectal cancer. In total, 174 5-fluorouracil pretreated patients were randomised to: arm A (n=41), 350 mg m(-2) irinotecan as a 90-min i.v. infusion q3 weeks; arm B (n=38), 125 mg m(-2) irinotecan as a 90-min i.v. infusion weekly x 4 weeks q6 weeks; arm C (n=46), 250 mg m(-2) irinotecan as a 90-min i.v. infusion q2 weeks; or arm D (n=49), 10 mg m(-2) day(-1) irinotecan as a 14-day continuous infusion q3 weeks. No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months; P=0.02). Overall response rates were in the range 5-11%. Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months). Similarly, there were no significant differences in the incidence of grade 3-4 toxicities, although the toxicity profile between arms A, B, and C and D did differ. Generally, significantly less haematologic toxicity, alopecia and cholinergic syndrome were observed in arm D; however, there was a trend for increased gastrointestinal toxicity. Irinotecan is an effective and safe second-line treatment for colorectal cancer. The schedules examined yielded equivalent results, indicating that there is no advantage of the prolonged vs short infusion schedule

Localized acne induced by radiation therapy

The appearance of localized acne or comedo reaction during or shortly after radiotherapy is an unusual adverse event, but one that is probably underestimated. It can manifest as an inflammatory (papules, pustules, nodules), comedonal (open and closed comedones, Favre-Racouchot-like syndrome), or mixed presentation. We report two new cases of radiation-induced acne with different clinical aspects and discuss the main known features of this adverse event

Dermatological toxicities induced by T-cell-redirecting GPRC5D bispecific antibody talquetamab

Early trials with talquetamab showed that dermatological adverse events were among the most frequent, along with cytokine release syndrome, hematologic and neurotoxic effects (2). However, dermatological toxicities, which concerned up to 70% of exposed patients, have not been described to date. We conducted a monocentric descriptive retrospective study (from 2020 to 2022) at Comprehensive Cancer Center, IUC, Toulouse, France. All patients with refractory multiple myeloma and exposed to talquetamab, either in monotherapy (subcutaneous infusion, 400µg weekly) or in combination with pomalidomide, carfizomib or cetrelimab (300µg weekly to 800µg every two weeks) were evaluated in the oncodermatology department. The study was approved by the institutional review board (CRE IUCT-O: 2-22-02).THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV